Global Epigenetics Drugs Market
Global Epigenetics Drugs Market

Epigenetics Drugs Comprehensive Study by Application (Solid Tumors, Liquid Tumors, Inflammatory Diseases, Metabolic Diseases, Infectious Diseases, Cardiovascular Diseases), Mechanism of Action (DNMT Inhibitors (Azacitidine and Decitabine), HDAC Inhibitors (Vorinostat and Romidepsin)) Players and Region - Global Market Outlook to 2024

Epigenetics Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Feb 2019 Edition 208 Pages 182 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Epigenetics is referred to as the study of heritable and reversible forms of gene regulation which are not dependent on the DNA sequence. This regulation basically includes DNA methylation and also histone methylation, ubiquitination, acetylation, and phosphorylation. Epigenetic drugs which are designed to fight cancer might also be used against many of the viruses. Epigenetics Drugs market is expected to witness moderate growth during the forecast period, which is owing to the rise in the epigenetic drug discovery. Furthermore, a surge in the prevalence of cancer and some of the technological advancements in the epigenetics research are anticipated to augmented the market growth

Market Drivers
  • Increase in Demand for the Treatment of Oncology and Non-Oncology Conditions
  • Huge Amounts of Investment

Market Trend
  • Advancement In the Screening Tools

Restraints
  • The Genericization Of Major Drugs

Opportunities
Growing Technological Advancement Related To Product Market

Players Covered in the Study are:
Astex Pharmaceuticals Inc. (United Kingdom), Cellcentric Ltd. (United States), Celleron Therapeutics Ltd. (United States), Celgene Corporation (United States), Epigentek Group Inc. (United States), Eisai Co. Ltd. (Japan), Epizyme, Inc. (United States), Illumina Inc. (United States), Mdxhealth (Belgium) and Merck & Company Inc. (United States)

The Global Epigenetics Drugs market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Industry Insights:
MDxHealth signs partnership with LifeLabs to make SelectMDx available in Canada. LifeLabs is a leading Canadian company that performs over 100 million laboratory tests per year to help diagnose, treat, monitor and prevent diseases, supporting over 19 million patient visits annually

Available Customization:
List of players that can be included in the study on immediate basis are Novartis International AG (Switzerland), Oncolys Biopharma Inc. (Japan), Pharmacyclics, Inc. (United States) and Promega Corporation (United States).

Report Objectives / Segmentation Covered
By Application
  • Solid Tumors
  • Liquid Tumors
  • Inflammatory Diseases
  • Metabolic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
By Mechanism of Action
  • DNMT Inhibitors [Azacitidine and Decitabine]
  • HDAC Inhibitors [Vorinostat and Romidepsin]

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Demand for the Treatment of Oncology and Non-Oncology Conditions
      • 3.2.2. Huge Amounts of Investment
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Associated With The Product Can Hamper The Trust Among The Growing Population
    • 3.4. Market Trends
      • 3.4.1. Advancement In the Screening Tools
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Epigenetics Drugs, by Application, Mechanism of Action and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Epigenetics Drugs (Value)
      • 5.2.1. Global Epigenetics Drugs by: Application (Value)
        • 5.2.1.1. Solid Tumors
        • 5.2.1.2. Liquid Tumors
        • 5.2.1.3. Inflammatory Diseases
        • 5.2.1.4. Metabolic Diseases
        • 5.2.1.5. Infectious Diseases
        • 5.2.1.6. Cardiovascular Diseases
      • 5.2.2. Global Epigenetics Drugs by: Mechanism of Action (Value)
        • 5.2.2.1. DNMT Inhibitors [Azacitidine and Decitabine]
        • 5.2.2.2. HDAC Inhibitors [Vorinostat and Romidepsin]
      • 5.2.3. Global Epigenetics Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Epigenetics Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astex Pharmaceuticals Inc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cellcentric Ltd. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celleron Therapeutics Ltd. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celgene Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Epigentek Group Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eisai Co. Ltd. (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Epizyme, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Illumina Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mdxhealth (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Company Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Epigenetics Drugs Sale, by Application, Mechanism of Action and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Epigenetics Drugs (Value)
      • 7.2.1. Global Epigenetics Drugs by: Application (Value)
        • 7.2.1.1. Solid Tumors
        • 7.2.1.2. Liquid Tumors
        • 7.2.1.3. Inflammatory Diseases
        • 7.2.1.4. Metabolic Diseases
        • 7.2.1.5. Infectious Diseases
        • 7.2.1.6. Cardiovascular Diseases
      • 7.2.2. Global Epigenetics Drugs by: Mechanism of Action (Value)
        • 7.2.2.1. DNMT Inhibitors [Azacitidine and Decitabine]
        • 7.2.2.2. HDAC Inhibitors [Vorinostat and Romidepsin]
      • 7.2.3. Global Epigenetics Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Epigenetics Drugs: by Application(USD Million)
  • Table 2. Epigenetics Drugs Solid Tumors , by Region USD Million (2013-2018)
  • Table 3. Epigenetics Drugs Liquid Tumors , by Region USD Million (2013-2018)
  • Table 4. Epigenetics Drugs Inflammatory Diseases , by Region USD Million (2013-2018)
  • Table 5. Epigenetics Drugs Metabolic Diseases , by Region USD Million (2013-2018)
  • Table 6. Epigenetics Drugs Infectious Diseases , by Region USD Million (2013-2018)
  • Table 7. Epigenetics Drugs Cardiovascular Diseases , by Region USD Million (2013-2018)
  • Table 8. Epigenetics Drugs: by Mechanism of Action(USD Million)
  • Table 9. Epigenetics Drugs DNMT Inhibitors [Azacitidine and Decitabine] , by Region USD Million (2013-2018)
  • Table 10. Epigenetics Drugs HDAC Inhibitors [Vorinostat and Romidepsin] , by Region USD Million (2013-2018)
  • Table 11. South America Epigenetics Drugs, by Country USD Million (2013-2018)
  • Table 12. South America Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 13. South America Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 14. Brazil Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 15. Brazil Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 16. Argentina Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 17. Argentina Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 18. Rest of South America Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 19. Rest of South America Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 20. Asia Pacific Epigenetics Drugs, by Country USD Million (2013-2018)
  • Table 21. Asia Pacific Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 22. Asia Pacific Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 23. China Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 24. China Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 25. Japan Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 26. Japan Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 27. India Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 28. India Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 29. South Korea Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 30. South Korea Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 31. Taiwan Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 32. Taiwan Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 33. Australia Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 34. Australia Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 35. Rest of Asia-Pacific Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 36. Rest of Asia-Pacific Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 37. Europe Epigenetics Drugs, by Country USD Million (2013-2018)
  • Table 38. Europe Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 39. Europe Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 40. Germany Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 41. Germany Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 42. France Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 43. France Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 44. Italy Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 45. Italy Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 46. United Kingdom Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 47. United Kingdom Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 48. Netherlands Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 49. Netherlands Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 50. Rest of Europe Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 51. Rest of Europe Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 52. MEA Epigenetics Drugs, by Country USD Million (2013-2018)
  • Table 53. MEA Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 54. MEA Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 55. Middle East Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 56. Middle East Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 57. Africa Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 58. Africa Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 59. North America Epigenetics Drugs, by Country USD Million (2013-2018)
  • Table 60. North America Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 61. North America Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 62. United States Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 63. United States Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 64. Canada Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 65. Canada Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 66. Mexico Epigenetics Drugs, by Application USD Million (2013-2018)
  • Table 67. Mexico Epigenetics Drugs, by Mechanism of Action USD Million (2013-2018)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Epigenetics Drugs: by Application(USD Million)
  • Table 79. Epigenetics Drugs Solid Tumors , by Region USD Million (2019-2024)
  • Table 80. Epigenetics Drugs Liquid Tumors , by Region USD Million (2019-2024)
  • Table 81. Epigenetics Drugs Inflammatory Diseases , by Region USD Million (2019-2024)
  • Table 82. Epigenetics Drugs Metabolic Diseases , by Region USD Million (2019-2024)
  • Table 83. Epigenetics Drugs Infectious Diseases , by Region USD Million (2019-2024)
  • Table 84. Epigenetics Drugs Cardiovascular Diseases , by Region USD Million (2019-2024)
  • Table 85. Epigenetics Drugs: by Mechanism of Action(USD Million)
  • Table 86. Epigenetics Drugs DNMT Inhibitors [Azacitidine and Decitabine] , by Region USD Million (2019-2024)
  • Table 87. Epigenetics Drugs HDAC Inhibitors [Vorinostat and Romidepsin] , by Region USD Million (2019-2024)
  • Table 88. South America Epigenetics Drugs, by Country USD Million (2019-2024)
  • Table 89. South America Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 90. South America Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 91. Brazil Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 92. Brazil Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 93. Argentina Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 94. Argentina Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 95. Rest of South America Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 96. Rest of South America Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 97. Asia Pacific Epigenetics Drugs, by Country USD Million (2019-2024)
  • Table 98. Asia Pacific Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 99. Asia Pacific Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 100. China Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 101. China Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 102. Japan Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 103. Japan Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 104. India Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 105. India Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 106. South Korea Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 107. South Korea Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 108. Taiwan Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 109. Taiwan Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 110. Australia Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 111. Australia Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 112. Rest of Asia-Pacific Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 113. Rest of Asia-Pacific Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 114. Europe Epigenetics Drugs, by Country USD Million (2019-2024)
  • Table 115. Europe Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 116. Europe Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 117. Germany Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 118. Germany Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 119. France Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 120. France Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 121. Italy Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 122. Italy Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 123. United Kingdom Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 124. United Kingdom Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 125. Netherlands Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 126. Netherlands Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 127. Rest of Europe Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 128. Rest of Europe Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 129. MEA Epigenetics Drugs, by Country USD Million (2019-2024)
  • Table 130. MEA Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 131. MEA Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 132. Middle East Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 133. Middle East Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 134. Africa Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 135. Africa Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 136. North America Epigenetics Drugs, by Country USD Million (2019-2024)
  • Table 137. North America Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 138. North America Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 139. United States Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 140. United States Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 141. Canada Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 142. Canada Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 143. Mexico Epigenetics Drugs, by Application USD Million (2019-2024)
  • Table 144. Mexico Epigenetics Drugs, by Mechanism of Action USD Million (2019-2024)
  • Table 145. Research Programs/Design for This Report
  • Table 146. Key Data Information from Secondary Sources
  • Table 147. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Epigenetics Drugs: by Application USD Million (2013-2018)
  • Figure 5. Global Epigenetics Drugs: by Mechanism of Action USD Million (2013-2018)
  • Figure 6. South America Epigenetics Drugs Share (%), by Country
  • Figure 7. Asia Pacific Epigenetics Drugs Share (%), by Country
  • Figure 8. Europe Epigenetics Drugs Share (%), by Country
  • Figure 9. MEA Epigenetics Drugs Share (%), by Country
  • Figure 10. North America Epigenetics Drugs Share (%), by Country
  • Figure 11. Global Epigenetics Drugs share by Players 2018 (%)
  • Figure 12. Global Epigenetics Drugs share by Players (Top 3) 2018(%)
  • Figure 13. Global Epigenetics Drugs share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Astex Pharmaceuticals Inc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. Astex Pharmaceuticals Inc. (United Kingdom) Revenue: by Geography 2018
  • Figure 17. Cellcentric Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Cellcentric Ltd. (United States) Revenue: by Geography 2018
  • Figure 19. Celleron Therapeutics Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Celleron Therapeutics Ltd. (United States) Revenue: by Geography 2018
  • Figure 21. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 22. Celgene Corporation (United States) Revenue: by Geography 2018
  • Figure 23. Epigentek Group Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Epigentek Group Inc. (United States) Revenue: by Geography 2018
  • Figure 25. Eisai Co. Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Eisai Co. Ltd. (Japan) Revenue: by Geography 2018
  • Figure 27. Epizyme, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Epizyme, Inc. (United States) Revenue: by Geography 2018
  • Figure 29. Illumina Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Illumina Inc. (United States) Revenue: by Geography 2018
  • Figure 31. Mdxhealth (Belgium) Revenue, Net Income and Gross profit
  • Figure 32. Mdxhealth (Belgium) Revenue: by Geography 2018
  • Figure 33. Merck & Company Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Company Inc. (United States) Revenue: by Geography 2018
  • Figure 35. Global Epigenetics Drugs: by Application USD Million (2019-2024)
  • Figure 36. Global Epigenetics Drugs: by Mechanism of Action USD Million (2019-2024)
  • Figure 37. South America Epigenetics Drugs Share (%), by Country
  • Figure 38. Asia Pacific Epigenetics Drugs Share (%), by Country
  • Figure 39. Europe Epigenetics Drugs Share (%), by Country
  • Figure 40. MEA Epigenetics Drugs Share (%), by Country
  • Figure 41. North America Epigenetics Drugs Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Astex Pharmaceuticals Inc. (United Kingdom)
  • Cellcentric Ltd. (United States)
  • Celleron Therapeutics Ltd. (United States)
  • Celgene Corporation (United States)
  • Epigentek Group Inc. (United States)
  • Eisai Co. Ltd. (Japan)
  • Epizyme, Inc. (United States)
  • Illumina Inc. (United States)
  • Mdxhealth (Belgium)
  • Merck & Company Inc. (United States)
Additional players considered in the study are as follows:
Novartis International AG (Switzerland) , Oncolys Biopharma Inc. (Japan) , Pharmacyclics, Inc. (United States) , Promega Corporation (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation